Seagen, LAVA Therapeutics Ink Worldwide License Agreement To Develop And Commercialize LAVA-1223

Pfizer Closes $43 Bln All-cash Acquisition Of Seagen

Pfizer Inc. (PFE) announced Thursday the successful completion of its acquisition of biotechnology company Seagen Inc. (SGEN). Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.

RTTNews | Před 598 dny

Pfizer Receives All Required Regulatory Approvals To Complete Seagen Acquisition

Pfizer Inc. (PFE) announced Tuesday that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer's pending acquisition of Seagen Inc. (SGEN).

RTTNews | Před 600 dny

Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints

Merck & Co Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Friday positive topline results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen Inc. (SGEN) and Astellas Pharma Inc. (ALPMY.PK, ALPMY).

RTTNews | Před 681 dny

LAVA Therapeutics Appoints Dr. Charles Morris As Chief Medical Officer

Immuno-oncology company LAVA Therapeutics N.V. (LVTX) announced Monday that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd.

RTTNews | Před 909 dny

Seagen Appoints David Epstein As New CEO

Biotechnology company Seagen Inc. (SGEN) announced Thursday that its Board of Directors has appointed David Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors.

RTTNews | Před 997 dny

Sensex, Nifty Give Up Early Gains; IT And Pharma Stocks Drag

Indian shares were little changed on Monday, giving up some early gains, with rising trade tensions with the U.S., mixed earnings results and continued foreign fund outflows keeping investors on edge.

RTTNews | Před 49 minutami

Australian Market Extends Early Losses In Mid-market

The Australian stock market is extending its early losses in choppy mid-market trading on Monday, also adding to the losses in the previous two sessions, following the broadly negative cues from Wall Street on Friday. The benchmark S&P/ASX 200 index is falling below the 8,650.00 level, with weakness in energy, financial and technology stocks partially offset by strong gains in mining stocks.

RTTNews | Před 1 h 28 min

Asian Markets Trade Mixed

Asian stock markets are trading mixed on Monday, following the negative cues from Wall Street on Friday, amid concerns about the economic impact of US President Donald Trump's unilateral "reciprocal tariffs" and aggressive trade stance on the global economy. However, the weaker than expected US monthly jobs data increased optimism about a potential interest rate cut by the US Fed in September.

RTTNews | Před 2 h 9 min

EURUSD	1.15796	GBPUSD	1.32801	AUDUSD	0.64833
USDJPY	147.672	USDCAD	1.37701	USDCHF	0.80516

Advertisement

Seagen, LAVA Therapeutics Ink Worldwide License Agreement To Develop And Commercialize LAVA-1223